Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up

Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent protections and that the rival has “improperly compared” the companies’ assets publicly.